Amgen Inc.
TRANSTHYRETIN IMMUNOGLOBULIN FUSIONS

Last updated:

Abstract:

The present invention relates to transthyretin (TTR) fusions useful in the dimerization and tetramerization of antibodies and antibody fragments, such as Fabs. The TTR fusions proteins described herein are particularly useful in increasing antibody avidity and in enhancing antigen clustering. Methods for treating diseases using the fusion proteins of the present invention are described herein.

Status:
Application
Type:

Utility

Filling date:

3 Oct 2018

Issue date:

8 Oct 2020